檢索結果 - Ukropec, Jon

Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma 由 Fonseca, Rafael, Usmani, Saad Z., Mehra, Maneesha, Slavcev, Mary, He, Jianming, Cote, Sarah, Lam, Annette, Ukropec, Jon, Maiese, Eric M., Nair, Sandhya, Potluri, Ravi, Voorhees, Peter M.

獲取全文 獲取全文 獲取全文

Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN 由 Voorhees, Peter M., Rodriguez, Cesar, Reeves, Brandi, Nathwani, Nitya, Costa, Luciano J., Lutska, Yana, Bobba, Padma, Hoehn, Daniela, Pei, Huiling, Ukropec, Jon, Qi, Ming, Lin, Thomas S., Richardson, Paul G.

獲取全文 獲取全文 獲取全文

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study 由 Yimer, Habte, Melear, Jason, Faber, Edward, Bensinger, William I., Burke, John M., Narang, Mohit, Stevens, Don, Gunawardena, Sriya, Lutska, Yana, Qi, Keqin, Ukropec, Jon, Qi, Ming, Lin, Thomas S., Rifkin, Robert M.

獲取全文 獲取全文 獲取全文

Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia 由 Cook, Gordon, Corso, Alessandro, Streetly, Matthew, Mendeleeva, Larisa P., Ptushkin, Vadim V., Chan, Edmond, Ukropec, Jon, Iraqi, Wafae, Al-Akabawi, Assem, Pei, Huiling, Gaudig, Maren, Petrucci, Maria Teresa, Alegre, Adrian, Mateos, Maria-Victoria

獲取全文 獲取全文 獲取全文

Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma 由 Chari, Ajai, Lonial, Sagar, Mark, Tomer M., Krishnan, Amrita Y., Stockerl‐Goldstein, Keith E., Usmani, Saad Z., Londhe, Anil, Etheredge, Delores, Fleming, Sarah, Liu, Baolian, Ukropec, Jon, Lin, Thomas S., Jagannath, Sundar, Nooka, Ajay K.

獲取全文 獲取全文 獲取全文

Early M‐Protein Dynamics Predicts Progression‐Free Survival in Patients With Relapsed/Refractory Multiple Myeloma 由 Yan, Xiaoyu, Xu, Xu Steven, Weisel, Katja C., Mateos, Maria‐Victoria, Sonneveld, Pieter, Dimopoulos, Meletios A., Usmani, Saad Zafar, Bahlis, Nizar J., Puchalski, Thomas, Ukropec, Jon, Bellew, Kevin, Ming, Qi, Sun, Steven, Zhou, Honghui

獲取全文 獲取全文 獲取全文

A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma 由 Munshi, Nikhil C., Avet-Loiseau, Herve, Anderson, Kenneth C., Neri, Paola, Paiva, Bruno, Samur, Mehmet, Dimopoulos, Meletios, Kulakova, Margarita, Lam, Annette, Hashim, Mahmoud, He, Jianming, Heeg, Bart, Ukropec, Jon, Vermeulen, Jessica, Cote, Sarah, Bahlis, Nizar

獲取全文 獲取全文 獲取全文

Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses 由 Xu, Xu Steven, Moreau, Philippe, Usmani, Saad Z., Lonial, Sagar, Jakubowiak, Andrzej, Oriol, Albert, Krishnan, Amrita, Bladé, Joan, Luo, Man, Sun, Yu-Nien, Zhou, Honghui, Nnane, Ivo, Deraedt, William, Qi, Ming, Ukropec, Jon, Clemens, Pamela L.

獲取全文 獲取全文 獲取全文

Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma 由 Chari, Ajai, Martinez-Lopez, Joaquín, Mateos, María-Victoria, Bladé, Joan, Benboubker, Lotfi, Oriol, Albert, Arnulf, Bertrand, Rodriguez-Otero, Paula, Pineiro, Luis, Jakubowiak, Andrzej, de Boer, Carla, Wang, Jianping, Clemens, Pamela L., Ukropec, Jon, Schecter, Jordan, Lonial, Sagar, Moreau, Philippe

獲取全文 獲取全文 獲取全文

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study 由 Bahlis, Nizar J., Dimopoulos, Meletios A., White, Darrell J., Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Ho, P. Joy, Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Kaufman, Jonathan L., Krevvata, Maria, Chiu, Christopher, Qin, Xiang, Okonkwo, Linda, Trivedi, Sonali, Ukropec, Jon, Qi, Ming, San-Miguel, Jesus

獲取全文 獲取全文 獲取全文

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and... 由 Mateos, Maria-Victoria, Spencer, Andrew, Nooka, Ajay K., Pour, Ludek, Weisel, Katja, Cavo, Michele, Laubach, Jacob P., Cook, Gordon, Iida, Shinsuke, Benboubker, Lotfi, Usmani, Saad Z., Yoon, Sung-Soo, Bahlis, Nizar J., Chiu, Christopher, Ukropec, Jon, Schecter, Jordan M., Qin, Xiang, O’Rourke, Lisa, Dimopoulos, Meletios A.

獲取全文 獲取全文 獲取全文

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR 由 Avet-Loiseau, Hervé, San-Miguel, Jesus, Casneuf, Tineke, Iida, Shinsuke, Lonial, Sagar, Usmani, Saad Z., Spencer, Andrew, Moreau, Philippe, Plesner, Torben, Weisel, Katja, Ukropec, Jon, Chiu, Christopher, Trivedi, Sonali, Amin, Himal, Krevvata, Maria, Ramaswami, Priya, Qin, Xiang, Qi, Mia, Sun, Steven, Qi, Ming, Kobos, Rachel, Bahlis, Nizar J.

獲取全文 獲取全文 獲取全文

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE 由 San-Miguel, Jesus, Avet-Loiseau, Hervé, Paiva, Bruno, Kumar, Shaji, Dimopoulos, Meletios A., Facon, Thierry, Mateos, María-Victoria, Touzeau, Cyrille, Jakubowiak, Andrzej, Usmani, Saad Z., Cook, Gordon, Cavo, Michele, Quach, Hang, Ukropec, Jon, Ramaswami, Priya, Pei, Huiling, Qi, Mia, Sun, Steven, Wang, Jianping, Krevvata, Maria, DeAngelis, Nikki, Heuck, Christoph, Van Rampelbergh, Rian, Kudva, Anupa, Kobos, Rachel, Qi, Ming, Bahlis, Nizar J.

獲取全文 獲取全文 獲取全文

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA 由 Facon, Thierry, Cook, Gordon, Usmani, Saad Z., Hulin, Cyrille, Kumar, Shaji, Plesner, Torben, Touzeau, Cyrille, Bahlis, Nizar J., Basu, Supratik, Nahi, Hareth, Goldschmidt, Hartmut, Quach, Hang, Mohty, Mohamad, Venner, Christopher P., Weisel, Katja, Raje, Noopur, Hebraud, Benjamin, Belhadj-Merzoug, Karim, Benboubker, Lotfi, Decaux, Olivier, Manier, Salomon, Caillot, Denis, Ukropec, Jon, Pei, Huiling, Van Rampelbergh, Rian, Uhlar, Clarissa M., Kobos, Rachel, Zweegman, Sonja

獲取全文 獲取全文 獲取全文

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA 由 Cavo, Michele, San-Miguel, Jesus, Usmani, Saad Z., Weisel, Katja, Dimopoulos, Meletios A., Avet-Loiseau, Hervé, Paiva, Bruno, Bahlis, Nizar J., Plesner, Torben, Hungria, Vania, Moreau, Philippe, Mateos, Maria-Victoria, Perrot, Aurore, Iida, Shinsuke, Facon, Thierry, Kumar, Shaji, van de Donk, Niels W. C. J., Sonneveld, Pieter, Spencer, Andrew, Krevvata, Maria, Heuck, Christoph, Wang, Jianping, Ukropec, Jon, Kobos, Rachel, Sun, Steven, Qi, Mia, Munshi, Nikhil

獲取全文 獲取全文 獲取全文

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial 由 Voorhees, Peter M., Kaufman, Jonathan L., Laubach, Jacob, Sborov, Douglas W., Reeves, Brandi, Rodriguez, Cesar, Chari, Ajai, Silbermann, Rebecca, Costa, Luciano J., Anderson, Larry D., Nathwani, Nitya, Shah, Nina, Efebera, Yvonne A., Holstein, Sarah A., Costello, Caitlin, Jakubowiak, Andrzej, Wildes, Tanya M., Orlowski, Robert Z., Shain, Kenneth H., Cowan, Andrew J., Murphy, Sean, Lutska, Yana, Pei, Huiling, Ukropec, Jon, Vermeulen, Jessica, de Boer, Carla, Hoehn, Daniela, Lin, Thomas S., Richardson, Paul G.

獲取全文 獲取全文 獲取全文

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) 由 Mateos, María-Victoria, Kumar, Shaji, Dimopoulos, Meletios A., González-Calle, Verónica, Kastritis, Efstathios, Hajek, Roman, De Larrea, Carlos Fernández, Morgan, Gareth J., Merlini, Giampaolo, Goldschmidt, Hartmut, Geraldes, Catarina, Gozzetti, Alessandro, Kyriakou, Charalampia, Garderet, Laurent, Hansson, Markus, Zamagni, Elena, Fantl, Dorotea, Leleu, Xavier, Kim, Byung-Su, Esteves, Graça, Ludwig, Heinz, Usmani, Saad, Min, Chang-Ki, Qi, Ming, Ukropec, Jon, Weiss, Brendan M., Rajkumar, S. Vincent, Durie, Brian G. M., San-Miguel, Jesús

獲取全文 獲取全文 獲取全文

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX 由 Kaufman, Jonathan L., Dimopoulos, Meletios A., White, Darrell, Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Morton, James, Joy Ho, P., Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Sutherland, Heather J., Magen, Hila, Iida, Shinsuke, Kim, Jin Seok, Miles Prince, H., Cochrane, Tara, Oriol, Albert, Bahlis, Nizar J., Chari, Ajai, O’Rourke, Lisa, Trivedi, Sonali, Casneuf, Tineke, Krevvata, Maria, Ukropec, Jon, Kobos, Rachel, Avet-Loiseau, Hervé, Usmani, Saad Z., San-Miguel, Jesus

獲取全文 獲取全文 獲取全文

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk 由 Weisel, Katja, Spencer, Andrew, Lentzsch, Suzanne, Avet-Loiseau, Hervé, Mark, Tomer M., Spicka, Ivan, Masszi, Tamas, Lauri, Birgitta, Levin, Mark-David, Bosi, Alberto, Hungria, Vania, Cavo, Michele, Lee, Je-Jung, Nooka, Ajay, Quach, Hang, Munder, Markus, Lee, Cindy, Barreto, Wolney, Corradini, Paolo, Min, Chang-Ki, Chanan-Khan, Asher A., Horvath, Noemi, Capra, Marcelo, Beksac, Meral, Ovilla, Roberto, Jo, Jae-Cheol, Shin, Ho-Jin, Sonneveld, Pieter, Casneuf, Tineke, DeAngelis, Nikki, Amin, Himal, Ukropec, Jon, Kobos, Rachel, Mateos, Maria-Victoria

獲取全文 獲取全文 獲取全文